CoChat

Estrogen Treatment After Ovariectomy Protects Against Fatty Liver and May Improve Pathway-Selective Insulin Resistance

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Pathway-selective insulin resistance where insulin fails to suppress hepatic glucose production but promotes liver fat storage may underlie glucose and lipid abnormalities after menopause. We tested the mechanisms by which estrogen treatment may alter the impact of a high-fat diet (HFD) when given at the time of ovariectomy (OVX) in mice. Female C57BL/6J mice underwent sham operation, OVX, or OVX with estradiol (E2) treatment and were fed an HFD. Hyperinsulinemic-euglycemic clamps were used to assess insulin sensitivity, tracer incorporation into hepatic lipids, and liver triglyceride export. OVX mice had increased adiposity that was prevented with E2 at the time of OVX. E2 treatment increased insulin sensitivity with OVX and HFD. In sham and OVX mice, HFD feeding induced fatty liver, and insulin reduced hepatic apoB100 and liver triglyceride export. E2 treatment reduced liver lipid deposition and prevented the decrease in liver triglyceride export during hyperinsulinemia. In mice lacking the liver estrogen receptor α, E2 after OVX limited adiposity but failed to improve insulin sensitivity, to limit liver lipid deposition, and to prevent insulin suppression of liver triglyceride export. In conclusion, estrogen treatment may reverse aspects of pathway-selective insulin resistance by promoting insulin action on glucose metabolism but limiting hepatic lipid deposition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db11-1718

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Estrogen treatment at the time of OVX reduces diet-induced obesity. A: OVX led to increased body weight with HFD. Mice treated with E2 at the time of OVX did not gain weight with HFD. B: Adiposity was increased with HFD in sham mice and after OVX. Adiposity was reduced with E2 treatment. Letter B indicates baseline before HFD-feeding. Letter E indicates end point after HFD. C: Plasma cholesterol levels. D: Plasma triglyceride levels. E: HFD increased fasting insulin levels in sham and OVX mice, and E2 treatment reduced plasma insulin. F: Fasting glucose levels were not different between groups. *P < 0.05. For panel B, differences from baseline were defined by Student t test. For C–F, differences between groups were determined by ANOVA followed by Tukey post hoc tests.
FIG. 1. Estrogen treatment at the time of OVX reduces diet-induced obesity. A: OVX led to increased body weight with HFD. Mice treated with E2 at the time of OVX did not gain weight with HFD. B: Adiposity was increased with HFD in sham mice and after OVX. Adiposity was reduced with E2 treatment. Letter B indicates baseline before HFD-feeding. Letter E indicates end point after HFD. C: Plasma cholesterol levels. D: Plasma triglyceride levels. E: HFD increased fasting insulin levels in sham and OVX mice, and E2 treatment reduced plasma insulin. F: Fasting glucose levels were not different between groups. *P < 0.05. For panel B, differences from baseline were defined by Student t test. For C–F, differences between groups were determined by ANOVA followed by Tukey post hoc tests.CC BY-NC-ND · PubMed Central
FIG. 2. Estrogen treatment at the time of OVX reduces pathway-selective insulin resistance. A: Schematic of the hyperinsulinemic-euglycemic clamp study with triglyceride (TG) and glucose tracers. B: Euglycemia was maintained at ∼150 mg/dL during the clamp. C: GIR to maintain euglycemia. D: Insulin sensitivity index. E: Compared with baseline (no insulin), insulin failed to suppress EndoRa after OVX (plus insulin), but insulin did suppress EndoRa after OVX with E2 treatment. F: Total plasma triglyceride during the clamp study. G: Plasma 14C-triglyceride–specific activity (SA). *P < 0.05. Differences between groups were determined by ANOVA followed by Tukey post hoc tests.
FIG. 2. Estrogen treatment at the time of OVX reduces pathway-selective insulin resistance. A: Schematic of the hyperinsulinemic-euglycemic clamp study with triglyceride (TG) and glucose tracers. B: Euglycemia was maintained at ∼150 mg/dL during the clamp. C: GIR to maintain euglycemia. D: Insulin sensitivity index. E: Compared with baseline (no insulin), insulin failed to suppress EndoRa after OVX (plus insulin), but insulin did suppress EndoRa after OVX with E2 treatment. F: Total plasma triglyceride during the clamp study. G: Plasma 14C-triglyceride–specific activity (SA). *P < 0.05. Differences between groups were determined by ANOVA followed by Tukey post hoc tests.CC BY-NC-ND · PubMed Central
FIG. 3. Estrogen treatment at the time of OVX reduces fatty liver. A: Oil red O staining of liver neural lipid droplets. B–E: Liver lipids were extracted with the Folch method, and neutral lipids were separated by TLC as described in research design and methods. Triglyceride (TG) (B) and diacylglycerol (DAG) (D) were quantified using an enzymatic assay; 14C-triglyceride (C) and 14C-diacylglycerol (E) were quantified by scintillation counting. *P < 0.05. Differences between groups were determined by ANOVA followed by Tukey post hoc tests. (A high-quality digital representation of this figure is available in the online issue.)
FIG. 3. Estrogen treatment at the time of OVX reduces fatty liver. A: Oil red O staining of liver neural lipid droplets. B–E: Liver lipids were extracted with the Folch method, and neutral lipids were separated by TLC as described in research design and methods. Triglyceride (TG) (B) and diacylglycerol (DAG) (D) were quantified using an enzymatic assay; 14C-triglyceride (C) and 14C-diacylglycerol (E) were quantified by scintillation counting. *P < 0.05. Differences between groups were determined by ANOVA followed by Tukey post hoc tests. (A high-quality digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
FIG. 4. Estrogen treatment blocks insulin (Ins)-mediated dephosphorylation of ACC and insulin reduction of apoB100 in the liver. Livers from mice in a cohort that was fasted but not clamped (−) and after hyperinsulinemic clamp study (+) were used for protein extraction and Western blotting. A: pACC and total ACC. Expression of actin and Panseau S staining were used as loading controls. ACC expression and the ratio of pACC to ACC were quantified in B and C. D: Western blot for liver apoB100, MTP, and PLTP. Expression of apoB100 (E), MTP (F), and PLTP (G) was quantified as well. *P < 0.05. Differences (+ or − insulin) were defined by Student t test. Differences between groups were determined by ANOVA followed by Tukey post hoc tests.
FIG. 4. Estrogen treatment blocks insulin (Ins)-mediated dephosphorylation of ACC and insulin reduction of apoB100 in the liver. Livers from mice in a cohort that was fasted but not clamped (−) and after hyperinsulinemic clamp study (+) were used for protein extraction and Western blotting. A: pACC and total ACC. Expression of actin and Panseau S staining were used as loading controls. ACC expression and the ratio of pACC to ACC were quantified in B and C. D: Western blot for liver apoB100, MTP, and PLTP. Expression of apoB100 (E), MTP (F), and PLTP (G) was quantified as well. *P < 0.05. Differences (+ or − insulin) were defined by Student t test. Differences between groups were determined by ANOVA followed by Tukey post hoc tests.CC BY-NC-ND · PubMed Central
FIG. 5. Estrogen treatment reduces body weight but does not prevent pathway-selective insulin (Ins) resistance in LKO mice. A: ERα protein amounts were decreased specifically in liver of LKO mice but not in other tissues. B: Weight gain with HFD was increased after OVX and prevented with E2 treatment in LKO mice and their wild-type (WT) littermates. C: OVX led to increased adiposity with HFD, which was prevented with E2 treatment in LKO mice and their littermates. Letter B indicates baseline before HFD-feeding. Letter E indicates end point after HFD. D: Euglycemia was maintained at ∼150 mg/dL during the clamp. E: GIR to maintain euglycemia. F: Estrogen treatment did not restore the insulin suppression of EndoRa after OVX in LKO mice (−, baseline period of clamp; clamp period). G: Plasma 14C-triglyceride (TG)-specific activity (SA) was not significantly different by E2 treatment after OVX in LKO mice. *P < 0.05. Differences from baseline (B) or end point (E) were defined by Student t test.
FIG. 5. Estrogen treatment reduces body weight but does not prevent pathway-selective insulin (Ins) resistance in LKO mice. A: ERα protein amounts were decreased specifically in liver of LKO mice but not in other tissues. B: Weight gain with HFD was increased after OVX and prevented with E2 treatment in LKO mice and their wild-type (WT) littermates. C: OVX led to increased adiposity with HFD, which was prevented with E2 treatment in LKO mice and their littermates. Letter B indicates baseline before HFD-feeding. Letter E indicates end point after HFD. D: Euglycemia was maintained at ∼150 mg/dL during the clamp. E: GIR to maintain euglycemia. F: Estrogen treatment did not restore the insulin suppression of EndoRa after OVX in LKO mice (−, baseline period of clamp; clamp period). G: Plasma 14C-triglyceride (TG)-specific activity (SA) was not significantly different by E2 treatment after OVX in LKO mice. *P < 0.05. Differences from baseline (B) or end point (E) were defined by Student t test.CC BY-NC-ND · PubMed Central
FIG. 6. Estrogen treatment fails to protect against fatty liver with HFD feeding in LKO mice after OVX. A–D: Liver lipids were extracted with the Folch method, and neutral lipids were separated by TLC as described in research design and methods. Triglyceride (TG) (A) and diacylglycerol (DAG) (C) were quantified using an enzymatic assay; 14C-triglyceride (B) and 14C-diacylglycerol (D) were quantified by scintillation counting. E: Livers from mice in a cohort that was fasted but not clamped (−) and after hyperinsulinemic clamp study (+) were used for protein extraction and Western blotting for pACC, total ACC, apoB100, MTP, and PLTP. Expression of actin and Panseau S staining were used as loading controls.
FIG. 6. Estrogen treatment fails to protect against fatty liver with HFD feeding in LKO mice after OVX. A–D: Liver lipids were extracted with the Folch method, and neutral lipids were separated by TLC as described in research design and methods. Triglyceride (TG) (A) and diacylglycerol (DAG) (C) were quantified using an enzymatic assay; 14C-triglyceride (B) and 14C-diacylglycerol (D) were quantified by scintillation counting. E: Livers from mice in a cohort that was fasted but not clamped (−) and after hyperinsulinemic clamp study (+) were used for protein extraction and Western blotting for pACC, total ACC, apoB100, MTP, and PLTP. Expression of actin and Panseau S staining were used as loading controls.CC BY-NC-ND · PubMed Central
FIG. 7. Schematic representation of liver ERα signaling with regard to the regulation of liver glucose and lipid metabolism: HFD feeding after OVX resulted in pathway-selective insulin resistance where insulin failed to suppress hepatic glucose production (HGP), yet insulin was able to promote liver triglyceride (TG) storage by reducing hepatic apoB content, dephosphorylating ACC, and suppressing tracer incorporation into serum triglyceride. Estrogen treatment after OVX improved insulin suppression of hepatic glucose production and blocked insulin-mediated liver triglyceride storage.
FIG. 7. Schematic representation of liver ERα signaling with regard to the regulation of liver glucose and lipid metabolism: HFD feeding after OVX resulted in pathway-selective insulin resistance where insulin failed to suppress hepatic glucose production (HGP), yet insulin was able to promote liver triglyceride (TG) storage by reducing hepatic apoB content, dephosphorylating ACC, and suppressing tracer incorporation into serum triglyceride. Estrogen treatment after OVX improved insulin suppression of hepatic glucose production and blocked insulin-mediated liver triglyceride storage.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 326

Metadata

Authors
Zhu, L., Brown, W. C., Cai, Q., Krust, A., Chambon, P., McGuinness, O. P., & Stafford, J. M.
Affiliations
  • VA Tennessee Valley Healthcare System (US)
  • Vanderbilt University (US)
  • Institut de génétique et de biologie moléculaire et cellulaire (FR)
Corresponding author
Stafford, John M.
Venue
Diabetes
Published
2013-01-17
Volume
62
Issue
2
Pages
424-434
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2163187036
Cited by
326
References
50
Citations by year
2026: 19 · 2025: 24 · 2024: 23 · 2023: 21 · 2022: 23 · 2021: 28 · 2020: 25 · 2019: 36 · 2018: 25 · 2017: 23 · 2016: 18 · 2015: 26 · 2014: 22 · 2013: 13
FWCI
11.76
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • American Diabetes Association (DK20593)
  • U.S. Department of Veterans Affairs
  • John A. Hartford Foundation
  • American Heart Association (10GRNT3650024, DK20593)
  • Hartford Foundation for Public Giving
  • Atlantic Philanthropies
  • Vanderbilt University (DK20593)
  • National Institutes of Health (3p60dk020593-31s3)
  • Canadian Institutes of Health Research
  • Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center (DK-058404)
  • Vanderbilt Diabetes Research and Training Center, Vanderbilt University Medical Center (DK-20593)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK058404, P60-DK020593, DK59637, DK 20593, U24DK059637, P30DK058404, P30DK020593)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
estrogen, estradiol, ovariectomy, menopause, hepatic insulin sensitivity, hepatic steatosis, high-fat diet, hepatic lipid accumulation, adiposity, hepatic glucose production, hyperinsulinemic-euglycemic clamp
MeSH terms
Animals, Estradiol, Estrogens, Fatty Liver, Female, Glucose, Hyperinsulinism, Insulin Resistance, Lipids, Liver, Mice, Inbred C57BL, Obesity, Ovariectomy, Triglycerides, Glucose Clamp Technique, Estrogen Receptor alpha, Adiposity, Lipid Metabolism, Mice, Apolipoprotein B-100, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estrogen Treatment After Ovariectomy Protects Against Fatty Liver and May Improve Pathway-Selective Insulin Resistance. https://app.cochat.ai/papers/10.2337/db11-1718
The paper
Zhu, L., Brown, W. C., Cai, Q., Krust, A., Chambon, P., McGuinness, O. P., & Stafford, J. M. (2013). Estrogen Treatment After Ovariectomy Protects Against Fatty Liver and May Improve Pathway-Selective Insulin Resistance. Diabetes. https://doi.org/10.2337/db11-1718

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.